Resistance to protease inhibitors

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue SUPPL. 1, 2001, Pages

  Miller, V ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Cellular resistance; Cross resistance; Protease inhibitor resistance; Viral fitness; Virologic failure

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENZYME; ZIDOVUDINE;

CLINICAL TRIAL; CROSS RESISTANCE; DRUG APPROVAL; ENZYME STRUCTURE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0035280944     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200103011-00005     Document Type: Review

References (147)

1. HIV drug resistance
2. Protease inhibitors for the treatment of human immunodeficiency virus infection
3. Identification of biased amino acid substitution patterns in human immunodeficiency virus type I isolates from patients treated with protease inhibitors
4. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
5. Resistance to human immunodeficiency virus type 1 protease inhibitors
6. Rapid evolution of RNA genomes
7. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase
8. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
9. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
10. Viral dynamics in human immunodeficiency virus type 1 infection
11. Recombination in HIV-1
12. Human immunodeficiency virus type 1 subtypes defined by env show high frequency of recombinant gag genes
13. Pol gene diversity of five human immunodeficiency virus type 1 subtypes: Evidence for naturally occurring mutations thai contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D
14. Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient
15. A role for the aspartyl protease from the human immunodeficiency virus type 1 (HIV-1) in the orchestration of virus assembly
16. HTLV-III gag protein is processed in yeast cells by the virus pol-protease
17. Human immunodeficiency virus protease expressed in Escherichia coil exhibits autoprocessing and specific maturation of the gag precursor
18. Rote of human immunodeficiency virus type-1 specific protease in core protein maturation and viral infectivity
19. Retroviral protease-like sequence in the yeast transposon Ty 1
20. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1
21. Protease inhibitors: Resistance, cross-resistance, fitness and the choice of initial and salvage therapies
22. HIV protease: A novel chemotherapeutic target for AIDS
23. Properties of avian retrovirus particles defective in viral protease
24. Active human immunodeficiency virus protease is required for viral infectivity
25. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1
26. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles
27. Perspectives in HIV protease inhibitors
28. Protease inhibitors in patients with HIV disease
29. Human immunodeficiency virus type 1 protease inhibitors
30. Rational design of peptide-based HIV proteinase inhibitors
31. Design of enzyme inhibitors using iterative protein crystallographic analysis
32. Testing for HIV-1 drug resistance: New developments and clinical implications
33. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials
34. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type I protease: Relationship to drug resistance
35. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies
36. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites
37. Loss of viral fitness associated with multiple gag and gag-pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
38. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
39. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
40. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959
41. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959
42. Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase
43. Human immunodeficiency virus: Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex
44. Genotypic and phenotypic analysis of the protease gene in HIV-1-infected patients that failed long-term saquinavir therapy and switched to other protease inhibitors
45. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor
46. 2 symmetry-based diol inhibitors of HIV-1 protease
47. Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics
48. Activated dynamics of flap opening in HIV-1 protease
49. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
50. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors
51. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
52. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
53. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
54. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV-1 infection
55. Genetic correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure
56. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance
57. Kinetic characterization of human immunodeficiency virus type protease-resistant variants
58. 141W94 with or without zidovudine/3TC in patients with no prior protease inhibitor or 3TC therapy-ACTG 347
59. Development of amprenavir resistance in NRTI-experienced patients: Alternative mechanisms and correlation with baseline resistance to concomitant NRTIs
60. Resistance to the HIV protease inhibitor amprenavir in vitro and in clinical studies
61. Baseline (BL) HIV-1 protease (PR) and reverse transcriptase (RT) genotype as a predictor of response to ZDV + 3TC + indinavir (IDV)
62. Amprenavir (APV) shows less protease inhibitor (PI) cross resistance as compared with other PIs in a multiexperienced HIV cohort (CNAB3008, French Virological Substudy)
63. Protease inhibitor resistance in HIV: Correlation between phenotype and genotype
64. Differences in protease inhibitor (PI) phenotypic susceptibility after failure of the first PI-containing regimen
65. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
66. A phase Il study of amprenavir (141W94, agenerase) in antiretroviral-experienced children with HIV infection
67. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor
68. Tipranavir is active against a large selection of highly protease inhibitor-resistant HIV-1 clinical samples
69. In vitro selection and characterization of HIV-1 variants with increased resistance to ABT 378, a novel protease inhibitor
70. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632
71. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
72. Gag protein under selective antiretroviral pressure
73. HIV-1 gag cleavage site changes are associated with specific protease mutations in plasma HIV-1 RNA but are not always retained in replication-competent, protease inhibitor-resistant recombinant viruses
74. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
75. Pattern of specific mutations in HIV-1 protease that confer resistance to a panel of protease inhibitors
76. Selection of saquinavir-resistant mutants by indinavir following a switch from saquinavir
77. Relationship of baseline genotype to RNA response in ACTG 333 after switching from long term saquinavir (SQVhc) to indinavir (IDV) or saquinavir soft gelatin capsule (SQVsgc)
78. Linkage of dimer stability and inhibitor binding for drag resistant HIV-I protease mutants at neutral pH
79. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture
80. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
81. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
82. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein
83. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
84. The pharmacological role of P-glycoprotein in the intestinal epithelium
85. HIV-1 protease inhibitors are substrates for the MDR 1 multidrug transporter
86. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity
87. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy
88. Lymph rode human immunodeficiency virus RNA levels and resistance mutations in patients receiving high-dose saquinavir
89. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
90. Therapy of HIV infections: Problems and prospects
91. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
92. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
93. Declining morbidity among patients with advanced immunodeficiency virus infection
94. Changing patterns of mortality across Europe in patients infected with HIV-1
95. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
96. Baseline genotypic predictors of virological outcome in a clinical trial of indinavir plus zidovudine plus lamivudine (ACTG 320)
97. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
98. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
99. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure
100. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
101. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
102. Virological response to protease inhibitor therapy in an HIV clinic cohort
103. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
104. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients
105. Maintenance anti-retroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
106. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: Genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS Clinical Trials Group Protocol 315
107. Resistance during early virological rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTG protocol 347
108. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection
109. Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: Virological evaluation of the AVANTI 2 and AVANTI 3 studies
110. Lamivudine resistance precedes nelfinavir and zidovudine resistance in patients who lose viral suppression while receiving nelfinavir in combination with lamivudine and zidovudine
111. Virologic response to indinavir (IDV), efavirenz (EFV) and adefovir (ADV) among patients failing nelfinavir (NFV)
112. Impact of drug resistance mutations on virologic response to salvage therapy
113. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
114. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
115. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons
116. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome
117. sgc, indinavir (IDV) or nelfinavir (NFV) in combination with amprenavir (APV), abacavir (ABC), efavirenz (EFZ) & adefovir (ADV) in patients (Pts) with protease inhibitor (PI) failure
118. Multi-drug rescue therapy (MDRT) in three cohorts of HIV-positive individuals
119. HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV Cohort
120. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
121. Comparison of viral resistance emerging over 48 weeks of therapy with IDV/COM vs ABC/COM (CNA3005)
122. Mutations at codons 10 and 36 of protease region in absence of primary mutations may correlate with virological outcome in naive patients starting a PI-containing HAART regimen
123. Prevalence of resistance-associated mutations in patients starting antivirals: Virological response after approximately 1 year of therapy
124. Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program
125. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
126. Virological and immunological response to mega-HAART salvage therapy after failure of multiple antiretroviral regimen
127. Prolonged viral suppression after introduction of a post HAART salvage regimen
128. GIGHAART: A rescue therapy for HIV patients with multiple HAART failures
129. Pharmacokinetic (PK) drug-interaction between amprenavir (APV) and ritonavir (RTV) in HIV-seronegative subjects after multiple, oral dosing
130. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals
131. ABT-378/ritonavir (ABT-378/r) in antiretroviral-naive HIV+ patients: 72 Weeks
132. ABT-378/ritonavir (ABT-378/r) suppresses HIV RNA to <400 copies/mi in 84% of PI-experienced patients at 48 weeks
133. Baseline genotype and phenotype do not predict response to ABT-378/ritonavir in PI-experienced patients at 24 and 48 weeks
134. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
135. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
136. Delayed immunologic deterioration among patients who virologically fail protease inhibitor-based therapy
137. The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load
138. Association of viral load, CD4 cell count, and treatment with clinical progression in HIV patients with very low CD4 cell counts: The EuroSIDA Cohort
139. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
140. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses
141. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients
142. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors
143. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors
144. Mega-HAART, resistance and drug holidays
145. Anfiretroviral treatment interruptions in patients with treatment failure: Analyses from the Frankfurt HIV Cohort
146. Virologic and immunologic evaluation of structured treatment interruptions (STD in patients experiencing long-term virologic failure